Furosemide controlled release - scPharmaceuticals

Drug Profile

Furosemide controlled release - scPharmaceuticals

Alternative Names: Furoscix; Furosemide micropump patch - scPharmaceuticals/Sensile Medical; sc2Wear furosemide Infusor - scPharmaceuticals/Sensile Medical; SCP-101

Latest Information Update: 19 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator scPharmaceuticals
  • Developer Johns Hopkins University; scPharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Small molecules; Sulfanilamides
  • Mechanism of Action Loop diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic heart failure
  • Phase II/III Decompensated heart failure
  • Phase II Heart failure

Most Recent Events

  • 21 Mar 2017 scPharmaceuticals withdraws a phase I/II trial in Decompensated heart failure in USA prior to enrolment of patients (NCT02721511)
  • 24 Jan 2017 scPharmaceuticals and Heart Failure Clinical Research Network initiate enrolment in a clinical trial for Decompensated heart failure in USA
  • 20 Dec 2016 scPharmaceuticals announces intention to submit NDA to FDA in early 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top